Skip to main content

FoxHollow Licenses Rosetta Resolver for Atherosclerosis Project with Merck

NEW YORK, March 13 (GenomeWeb News) - FoxHollow Technologies has licensed the Rosetta Resolver system for research on cardiovascular disease, Rosetta Biosoftware said today.


FoxHollow will use the application to correlate genetic profiles of human atherosclerotic plaque samples to develop therapies, according to a statement. The data for analysis comes from a September 2005 pharmacogenomic collaboration between FoxHollow and Merck.


Financial details were not released.


Rosetta Biosoftware is a business unit of Rosetta Inpharmatics, which is a wholly owned subsidiary of Merck.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.